The present clinical study is a single-center dose-finding, safety and feasibility study involving patients with mild bronchial asthma in Germany. Ectoin® inhalation solution has already shown marked therapeutic efficacy in animal models of allergen induced asthma and the purpose of the study is to investigate the safety and tolerability of Ectoin® inhalation solution in the treatment of asthma.
The AKITA²® inhalation system allows for homogeneous drug deposition of aerosolized Ectoin® within the periphery of the lungs in a consistent and reproducible manner. The system also has a smart card technology meaning that data on compliance and dosing can be recorded automatically for each patient.
“We believe that Ectoin® inhalation solution shows tremendous potential as a treatment for mild to moderate bronchial asthma and may also be effective in other lung affecting diseases, e.g. COPD”...
...
About bitop
bitop AG develops and markets its products on the basis of extremolytes, a group of natural substances, which is responsible for the stress resistance of extremophilic microorganisms. Based on the unique cell protective mechanisms, extremolytes build an innovative therapy approach. The aim is the development of highly effective, well tolerable and also preventively effective therapeutics. For the production of extremolytes bitop AG has developed proprietary biotechnological processes, allowing the worldwide exclusive production of ectoines and other extremolytes. The Company is privately held and located in Witten (Germany).
About Activaero
Activaero is the world leader in controlled breathing technologies for inhaled therapeutic agents. With stand alone inhalation products and inhalation systems available for clinical trials and marketing partnerships, Activaero’s technologies allow for the most precise and efficient patienttailored pulmonary delivery. Activaero currently has two products on the market, AKITA JET®, a patient-tailored controlled breathing system with a Smart Card that contains the patient dosing parameters and records the compliance, and Watchhaler™, a hand held delivery system tailored specifically to children. The company also has available a range of technologies ideal for the controlled delivery of inhaled therapeutics in the clinical trial setting (AKITA2®, LimiX) and tailored to specific partnerships. Activaero’s technological approach has been validated repeatedly in the clinical setting. The company is privately held and located in Gemünden (Wohra) and Munich in Germany and Dublin, Ohio in the USA... [PDF] Activaero's Press Release -
